Pazoren Tablet 200 mg contains Pazopanib Hydrochloride, an oral targeted therapy used for the treatment of advanced renal cell carcinoma (RCC) and certain soft tissue sarcomas. Pazopanib belongs to the class of tyrosine kinase inhibitors (TKIs), which work by blocking specific enzymes involved in tumor growth and angiogenesis (formation of new blood vessels).

By inhibiting vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor receptors (PDGFR), and c-Kit, Pazoren reduces blood supply to tumors, slowing their growth and progression. This targeted mechanism makes it a cornerstone in the management of advanced cancers where conventional chemotherapy may have limited efficacy.

Pazoren Tablet 200 mg provides a convenient oral dosing option for patients, allowing continuous therapy under oncologist supervision. It is typically used as monotherapy for patients with advanced disease or as part of a treatment plan tailored to individual response and tolerance.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Key Features

• Contains Pazopanib Hydrochloride 200 mg per tablet

• Oral tyrosine kinase inhibitor for targeted cancer therapy

• Effective in advanced renal cell carcinoma and certain soft tissue sarcomas

• Inhibits tumor angiogenesis and growth by blocking VEGFR, PDGFR, and c-Kit

• Convenient oral tablet formulation for once-daily dosing

• Administered under strict oncologist supervision

Indications

Pazoren Tablet 200 mg is indicated for:

• Advanced renal cell carcinoma (RCC): Treatment of patients with locally advanced or metastatic RCC

• Soft tissue sarcomas: Management of patients with unresectable or metastatic soft tissue sarcomas

• Patients who are not candidates for surgical intervention or require systemic therapy due to advanced disease

Regular monitoring of liver function, blood pressure, and other laboratory parameters is essential during therapy.

Mechanism of Action

Pazopanib Hydrochloride functions as a multi-targeted tyrosine kinase inhibitor, blocking pathways critical for tumor growth and blood vessel formation:

• Inhibits VEGFR-1, VEGFR-2, and VEGFR-3, reducing tumor angiogenesis

• Inhibits PDGFR-α/β, limiting tumor cell proliferation

• Inhibits c-Kit, affecting certain tumor cell survival pathways

By targeting these receptors, Pazoren effectively slows tumor growth, reduces vascular supply to the tumor, and improves disease control in advanced cancers.

Dosage and Administration

• Typically administered once daily orally, with or without food

• Tablets should be swallowed whole; do not crush or chew

• Dose adjustments may be required based on liver function, drug interactions, and patient tolerance

• Regular monitoring of blood pressure, liver enzymes, and blood counts is necessary

• Continuous therapy is usually recommended until disease progression or unacceptable toxicity

Possible Side Effects

Common side effects may include:

• Fatigue and weakness

• Nausea, vomiting, or diarrhea

• High blood pressure (hypertension)

• Hair depigmentation

• Loss of appetite

• Elevated liver enzymes

Serious but rare side effects include:

• Severe liver toxicity

• Cardiac issues (heart failure or arrhythmias)

• Bleeding or thromboembolic events

• Gastrointestinal perforation

Patients should report any unusual symptoms promptly to their healthcare provider.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Precautions

• Use under strict medical supervision

• Regular monitoring of liver function, blood pressure, and hematologic parameters is essential

• Avoid use in pregnancy or breastfeeding

• Inform the doctor about all other medications to prevent drug interactions, particularly CYP3A4 inhibitors or inducers

• Dose adjustments may be necessary for patients with hepatic impairment

Storage Instructions

• Store in a cool, dry place below 25°C

• Protect from moisture and light

• Keep tablets in the original container, tightly closed

• Keep out of reach of children.